Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.22%
Variazione Mensile
-1.20%
Variazione di 6 mesi
+19.57%
Variazione Annuale
-4.01%
Chiusura Precedente
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
Volume
76
Mercati
Mercato Azionario Statunitense
Salute
AVBP
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Notizie
Cantor Fitzgerald подтверждает рейтинг акций ArriVent как "Выше рынка"
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer подтверждает рейтинг Outperform для акций ArriVent BioPharma
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald начинает покрытие акций ArriVent BioPharma с рейтингом "Выше рынка"
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent дозирует первого пациента в ключевом исследовании препарата от рака легких
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
BTIG присвоил акциям ArriVent BioPharma рейтинг "Покупать"
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential